By News Plug Business Desk
The UK’s status as a life sciences hub is under pressure after major pharmaceutical companies confirmed they have paused almost £2 billion in planned investments this year. Industry leaders point to concerns over drug pricing, regulatory uncertainty, and a loss of international competitiveness as reasons for pulling back.
What’s Happening
According to industry figures reported in The Guardian, multinationals including MSD (known as Merck in the US), Eli Lilly, and AstraZeneca have delayed projects worth close to £2 billion. Executives say that while the UK government has promised to make Britain “a science superpower,” its current pricing system for medicines is undermining confidence (The Guardian).
One of the key sticking points is the Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG), which caps NHS spending on branded drugs. While designed to control health budgets, the scheme has drawn criticism from drugmakers who argue it squeezes returns and makes the UK a less attractive place to launch new treatments.
What the Companies Say
Pharma giants have been unusually open about their frustrations. Eli Lilly previously warned it was reconsidering investments in the UK due to what it called “commercial unviability” under the current rules. AstraZeneca’s chief executive Pascal Soriot has also cautioned that without reforms, Britain risks losing ground to countries with more predictable and profitable systems for drug approvals and pricing.
Merck (MSD) echoed these concerns, suggesting that while the UK has strong research institutions, the environment for turning science into business has become increasingly difficult.
Why It Matters
The life sciences sector is a cornerstone of the UK economy, employing around 280,000 people and contributing more than £30 billion a year in gross value added (ABPI). It has been one of the few industries able to compete on a global scale, particularly in drug discovery and clinical trials.
A pause in investment on this scale could slow the pipeline of new medicines, reduce high-value manufacturing, and weaken the UK’s ability to attract world-class research talent.
Government Response
The UK government insists it remains committed to making Britain “the best place in the world to invest in life sciences.” Ministers are currently negotiating with industry on the next version of VPAG, which is due for renewal. They argue that cost controls are essential for the NHS, but industry groups like the Association of the British Pharmaceutical Industry (ABPI) warn that if the balance isn’t right, investment will flow elsewhere (ABPI).
Conclusion
The freeze on £2 billion of pharma investments is more than a corporate stand-off. It signals a deeper tension between the UK’s desire to foster innovation and its need to control healthcare costs. If a compromise can’t be struck, Britain risks losing its place at the top table of global drug development — with consequences not just for the economy, but for patients waiting on the next generation of medicines.
